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1710 Abstracts December 2014other covariants the mean disease-speciﬁc quality of life score was slightly
worse after treatment with foam than after surgery (P ¼ .006) but was
similar in the laser and surgery groups. There were no signiﬁcant differences
between the surgery group and the foam or laser group in measures of
generic quality of life. The frequency of procedural complications was
similar in the foam group (6%) and the surgery group (7%) but was lower
in the laser group (1%) than in the surgery group (P < .001). The frequency
of serious adverse events was approximately 3% and was similar among the
groups. Measures of clinical success were also similar among the groups, but
successful ablation of the main trunks of the saphenous vein was less com-
mon in the foam group than in the surgery group (P < .001).
Comment: The three groups had similar improvements in venous
clinical severity score at 6 months, however ablation of the great saphenous
vein at 6 weeks occurred signiﬁcantly less often after foam treatment (com-
plete ablation 55%; partial ablation with a patent segment and no reﬂux
23%) than after either surgery (compete ablation 84%; partial ablation 6%)
or laser treatment (complete ablation 83%; partial ablation 8%). Long-
term follow-up therefore will be required to determine the durability of
these treatments and the frequency of patients seeking retreatment after
each of these forms of therapy of primary varicose veins. See also Abstract 5,
“Patient-Reported Outcomes 5-8 Years After Ultrasound-Guided Foam
Sclerotherapy for Varicose Veins” in this issue of the Journal.
Retrograde Aortic Dissection After Thoracic Endovascular Aortic
Repair
Canaud L, Ozdemir BA, Patterson BO, et al. Ann Surg 2014;260:389-95.
Conclusions: Retrograde type A aortic dissection (RTAD) after
TEVAR is an uncommon complication, but with a high mortality rate. It
occurs more frequently in patients treated for acute and chronic type B
dissection, and when the endograft is signiﬁcantly oversized.
Summary: Thoracic endovascular aortic repair (TEVAR) is utilized
for treatment of a wide variety of thoracic aortic pathologies. A potential le-
thal complication of this procedure is RTAD. So far, data with respect to
etiologic factors associated with RTAD are few and hampered by data qual-
ity and reporting parameters. The European Registry of Endovascular
Aortic Repair Complications reported 63 cases of RTAD among 4750
TEVAR procedures (Eggebrecht H et al, Circulation 2009;120:276-81).
While there’s a general consensus that RTAD may be more common in pa-
tients with acute type B aortic dissection there has been no deﬁnitive proven
association. In this study the authors sought to provide insight into the etio-
logical and procedural factors associated with RTAD following TEVAR.
Data were obtained from the MOTHER Registry (Patterson B et al, Circu-
lation 2013;127:24-32). These data were supplemented by cases from a sys-
tematic review of literature and data from both sources aggregated to report
the contemporary literature. Univariate analysis and binary logistic regres-
sion analysis of patient and technical factors was performed. In MOTHER,
RTAD developed in 16 of the 1010 patients (1.6%). Binary logistic regres-
sion demonstrated that an indication of TEVAR for aortic dissection (acute,
P ¼ .000212; chronic, P ¼ .006) and device oversizing (odds ratio, 1.14 per
1% increase in oversizing above 9%; P < .0001) were signiﬁcantly more
frequent in patients with RTAD. Data from the systematic review was
pooled with the MOTHER data and demonstrated that RTAD occurred
in 1.7% (168/9894). Most of RTAD occurred in the immediate postoper-
ative period (58%). Mortality rate was high at 33.6%. Odds ratio for RTAD
acute aortic dissection was 10.0 (95% conﬁdence interval, 4.7-21.9) and 3.4
(95% conﬁdence interval, 1.3-8.8) for chronic aortic dissection. Incidence of
RTAD was not signiﬁcantly different for endografts with a proximal bare
metal stent (2.8%) or a nonbare stent (1.9%; P ¼ .1298).
Comment: The majority of RTADs in this study occurred interopera-
tively (20.9%) or in the immediate postoperative period (50%). However,
29.1% suffered RTADmore than 30 days after the procedure. This combined
with the association with aortic endograft oversizing suggests that the
complication is likely related to a combination of natural progression of the
disease and fragility of the dissected aorta. Further studies should focus on
at what point after the occurrence of acute aortic dissection that the risk of
RTAD approaches that of treatment of a chronic aortic dissection and what
degree of aortic endograft oversizing is optimal to lower the risk of RTAD.
Patient-Reported Outcomes 5-8 Years After Ultrasound-Guided Foam
Sclerotherapy for Varicose Veins
Darvall KA, Bate GR, Bradbury AW. Br J Surg 2014;101:1098-104.
Conclusions: Ultrasound-guided foam sclerotherapy has durable results
as reported by patient-reported outcomes to at least 5 years. Only 15.3% of
limbs treated underwent retreatment for reoccurrence during follow-up.Summary: Treatment of varicose veins results in signiﬁcant improve-
ments in health-related quality of life (Baker DM et al, Eur J Vasc Endovasc
Surg 1995;9:299-304, and Michaels J et al, Br J Surg 2006;93:175-81). In
the UK the National Institute for Health and Care Excellence (NICE) vari-
cose vein clinical guideline published in July 2013 recommends patients
with symptomatic varicose veins, regardless of CEAP class, be referred for
assessment with duplex ultrasound imaging and consideration of interven-
tion, preferably by endovascular techniques (NICE guideline CG168, Lon-
don; 2013). However, to date few long-term data have been published on
venous interventions; with most existing reports continuing to focus on
technical outcomes rather than patient-reported outcome measures. Ultra-
sound-guided foam sclerotherapy (UGFS) has been reported to be clinically
effective with low rates of re-intervention in some studies but other studies
have raised concern that UGFS may not be as durable as surgery or endo-
thermal techniques. In this study the authors sought to investigate long-
term (5-8 years) outcomes following UGFS focusing on retreatment and
disease speciﬁc and generic health-related quality of life parameters, symp-
tom improvement, and meetings of patient expectations and overall patient
satisfaction. The study utilized consecutive patients undergoing UGFS be-
tween April 2004 and May 2007. Patients were invited for review at least
5 years after treatment. Patients completed generic (Short Form 12) and
disease-speciﬁc (Aberdeen Varicose Vein Symptom Severity Score, AVSS)
health-related quality of life questionnaires and questionnaires inquiring
about lower extremity symptoms, lifestyle factors, and satisfaction with
treatment. Data on retreatment was recorded prospectively. There were a
total of 391 limbs and 285 patients included (81.2% response rate) and a
median of 71 (interquartile range, 67-78) months following ﬁrst UGFS
treatment. Originally 72.1% had symptomatic uncomplicated varicose veins
while 21.9% had undergone previous surgery, and 82.7% had treatment of
great saphenous veins and 19.9% had treatment of the short saphenous
veins. Disease-speciﬁc health-related quality of life scores improved signiﬁ-
cantly at long-term follow-up, with 88.5% having an improved AVSS
compared with baseline. With respect to lower limb symptoms and lifestyle
improvement 62.7-93.8 per cent of patients had their pretreatment expec-
tations met or exceeded. 82% overall were very satisﬁed with their treat-
ments and only 3.3% were dissatisﬁed. 91% would recommend the
treatment to others. Kaplan-Meier analysis indicated 15.3% of limbs
required retreatment by 5 years.
Comment: In a recent systematic review the authors concluded that
endovenous laser treatment radio frequency ablation and UGFS and surgery
provided similar clinical outcomes in terms of reoccurrence, venous clinical
severity scores, short-term pain and quality of life (Carroll C et al, Health
Technol Assess 2013; 17 i-xvi, 1-141). The authors of the study point
out that this ﬁnding compared with general lower overall costs of UGFS
compared to endovenous thermal techniques and surgery suggest that
UGFS may be the most cost-effective option for treatment of varicose veins.
See also Abstract 3, “A Randomized Trial Comparing Treatments for Vari-
cose Veins” in this issue of the Journal.
Activities of Daily Living Is a Critical Factor in Predicting Outcome
After Carotid Endarterectomy in Asymptomatic Patients
Dayama A, Pimple P, Badrinathan B, et al. Stroke 2014;45:1703-8.
Conclusions: A patient’s inability to perform basic activities of inde-
pendent living is associated with adverse postoperative outcomes after ca-
rotid endarterectomy (CEA) for asymptomatic lesions.
Summary: The randomized trials of carotid endarterectomy both in
North America and Europe assessing the efﬁcacies of CEA for asymptomatic
disease generally excluded patients with a number of comorbid medical con-
ditions such as congestive heart failure, unstable angina, uncontrolled atrial
ﬁbrillation, or uncontrolled diabetes, etc. However, speciﬁc measures of
functional status were not utilized in patient stratiﬁcation in these trials.
The authors point out therefore that conventional models of stroke preven-
tion after CEA in asymptomatic patients have not been developed to accu-
rately predict outcomes in patients who are unable to perform activities of
daily living (Bekelis K et al, Stroke 2013;44: 1085-90). In this current study
the authors sought to assess the effect of preoperative functional status on
postoperative outcomes following CEA in asymptomatic patients. The hy-
pothesis was that preoperative functional disability would be associated
with worsened postoperative outcomes and in turn impaired survival of
the patients. Aided from the National Surgical Quality Improvement Proj-
ect, a national data set including data from more than 300 hospitals was uti-
lized in this study. Patients were identiﬁed by Current Procedural
Terminology (CPT) codes and divided into three categories based on func-
tional status; independent, partially dependent and dependent. Thirty-day
postoperative stroke, death and other postoperative complications were
identiﬁed as the study endpoint. Multivariate logistic regression analysis
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betes, cardiovascular disease, smoking, and other confounders. There were
19,748 patients with CEA analyzed of whom 19,348 (97.97%) were func-
tionally independent. 377 (1.99%) were functionally partially dependent and
23 (0.12%) were functionally dependent. In the functionally independent
group there were 196 (1.01%) strokes, 84 (0.43%) deaths, and 1416
(17.17%) other complications. In the functionally partially dependent
group, there were 14 (3.71%) strokes, 10 (2.65%) deaths, and 80
(21.22%) other complications. In a multivariable risk-adjusted model using
functionally independent as a reference, functionally partially dependent was
associated with death (odds ratio, 3.3; 95% CI, 1.6-6.8; P < .001), stroke
(odds ratio, 3; 95% CI, 1.7-5.4; P < .001), and other complications
(odds ratio, 2.5; 95% CI, 1.9-3.2; P < .001).
Comment: The complication rates in the patients with inability to
perform activities of daily living fall outside guidelines from the Society of
Vascular Surgery and the American Heart Association. It appears that activ-
ities of daily living are a critical factor in predicting outcomes after CEA in
asymptomatic patients and, in combination with improved medical manage-
ment of asymptomatic carotid stenosis, suggests that in patients with high-
grade asymptomatic carotid stenosis, aggressive medical management may
be the best option for patients with impaired activities of daily living and
high-grade asymptomatic carotid stenosis. In patients considered for CEA
for asymptomatic lesions functional status should be vigilantly assessed as
an aid in risk stratiﬁcation along with other objective factors for potentially
identifying increased risk of adverse outcome after CEA.
Volume of Carotid Artery Ulceration as a Predictor of Cardiovascular
Events
Kuk M, Wannarong T, Beletsky V, et al. Stroke 2014;45:1437-41.
Conclusions: With three-dimensional ultrasound volume of carotid
ulceration accurately predicts cardiovascular events.
Summary: Ulcerated carotid plaques have been associated with plaque
rupture, intraplaque hemorrhage, and overall decreased plaque stability. In
addition, ulceration tends to be associated with greater plaque thickness
and plaque volume (Homburg PJ et al, Stroke 2011;42:367-72, and Riccio
SA et al, Cardiovasc Ultrasound 2006;4:44). There also appears to be
increased stroke risk with ulcerated plaques (Eliasziw M et al, Stroke
1994;25:304-8). Studies of plaque ulceration in the past have characterized
the atherosclerotic plaque as complex with (irregular morphology with ul-
cers) or smooth or by quantifying the number of ulcers observed in a region
of interest. In this study the aim was to quantify carotid total ulcer volume by
three-dimensional ultrasound to investigate the relationship of total ulcer vol-
ume to vascular events (stroke, transient ischemic attack, myocardial infarc-
tion, revascularization, or death because of cardiovascular reason). There
were 349 at-risk subjects who provided written informed consent for carotid
three-dimensional ultrasound and whose plaques were then analyzed for ul-
cerations. Ulcer volume was deﬁned as a distinct discontinuity in an athero-
sclerotic plaque, with a volume of $1.00 mm3 as measured using manual
segmentation. The sum of the volumes of all ulcers seen in both carotids
was the total ulcer volume. Participants were monitored for#5 years for out-
comes including cardiovascular events and death. Kaplan-Meier survival anal-
ysis demonstrated that subjects with total ulcer volume$5 mm3 experienced
signiﬁcantly higher risk of developing stroke, transient ischemic attack, or
death (P ¼ .009) and of developing stroke/transient ischemic attack/
death/myocardial infarction/revascularization (P ¼ .017). Lower ulcer vol-
umes did not predict events and ulcer depth did not predict events.
Comment: Intuitively it makes sense that at some level characteristics
of the carotid plaque ought to have something to do with its propensity to
induce neurologic events. The authors take this concept a bit further in that
they can have demonstrated that volume of ulceration can be measured withthree-dimensional ultrasound and that this variable correlates with risk for a
variety of cardiovascular events. The implication is that the atherosclerotic
process in some patients may have a tendency to produce more unstable pla-
ques conferring greater risk for cardiovascular events to the patient and that
this risk can somehow be assessed through the use of three-dimensional ul-
trasound of the carotid plaque.
Aspirin for the Prevention of Recurrent Venous Thromboembolism:
The INSPIRE Collaboration
Simes J, Becattini C, Agnelli G, et al. Circulation 2014;130:1062-71.
Conclusions: Aspirin after anticoagulation treatment for venous
thromboembolism (VTE) reduces overall risk of reoccurrence by more
than a third in a broad cross-section of patients with a ﬁrst unprovoked
VTE without signiﬁcantly increasing risk of bleeding.
Summary: Unprovoked VTE has a high risk of reoccurrence after
discontinuation of vitamin K antagonist therapy. The risk is approximately
10% within the ﬁrst year and 5% per year thereafter (Boutitie F et al, BMJ
2011;342:d3036). The new oral anticoagulants can lower the risk of recur-
rent VTE as part of initial or extended therapy. They are effective alterna-
tives to warfarin but also carry bleeding risk and are expensive. Aspirin is
a potential low-cost and relatively safe means of preventing further VTE
events in the patient with an unprovoked VTE initially treated with antico-
agulants. Aspirin has been recently evaluated in the Aspirin for the Preven-
tion of Recurrent Venous Thromboembolism Warfarin and Aspirin
(WARFASA) and the Aspirin to Prevent Recurrent Venous Thromboembo-
lism (ASPIRE) trials (Becattini C et al, N Engl J Med 2012;366:1959-67,
and Brighton TA et al, N Engl J Med 2012;367:1979-87). These trials
demonstrated aspirin reduced the risk of recurrent VTE but were not indi-
vidually powered to detect moderate treatment effects for particular out-
comes or subgroups. Combined patient-level analysis of WARFASA and
ASPIRE was planned, and a protocol for the project was developed before
publishing and unblinding of the results of either trial. The purpose of the
INSPIRE analysis was to more accurately estimate the effects of aspirin
treatment; overall, on individual outcomes and in prespeciﬁed subgroups
of patients. Individual patient data analysis of these trials was performed
to assess the effect of aspiring, vs placebo on recurrent VTE, major vascular
events (recurrent VTE, myocardial infarction, stroke, and cardiovascular dis-
ease death) and bleeding, overall and within predeﬁned subgroups. The pri-
mary analysis for VTE, was by intention to treat using the time-to-event
data of 1224 patients, 193 had recurrent VTE over 30.4 months median
follow-up. Aspirin reduced recurrent VTE (7.5%/yr vs 5.1%/yr; hazard ra-
tio [HR], 0.68; 95% conﬁdence interval [CI], 0.51-0.90; P ¼ .008),
including both deep-vein thrombosis (HR, 0.66; 95% CI, 0.47-0.92; P ¼
.01) and pulmonary embolism (HR, 0.66; 95% CI, 0.41-1.06; P¼.08).
Aspirin reduced major vascular events (8.7%/yr vs 5.7%/yr; HR 0.66;
95% CI, 0.50-0.86; P ¼ .002). The major bleeding rate was low (0.4%/
yr for placebo and 0.5%/yr for aspirin). After adjustment for treatment
adherence, recurrent VTE was reduced by 42% (HR, 0.58; 95% CI, 0.40-
0.85; P ¼ .005). Prespeciﬁed subgroup analyses indicate similar relative,
but larger absolute, risk reductions in men and older patients.
Comment: While extended anticoagulation therapy is still the most
effective means of preventing recurrent VTE following unprovoked VTE,
such therapy is impractical and undesirable for most patients with initial
VTE events. The data here show that aspirin is a cheap, safe alternative to
reducing VTE risk following an initial period of anticoagulation for an
unprovoked initial VTE event. As such, it seems there is no reason to leave
patients completely unprotected for recurrent VTE events following an
initial period of anticoagulation. Aspirin reduces the risk of another VTE
event and is a safe treatment for these patients. Additional data will be
needed to know how long to continue aspirin in such patients and whether
the safety proﬁle continues over a longer periods of time.
